View Older Stories View More Recent Stories

Jul 17, 2023 08:00AM Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
Jul 10, 2023 08:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 23, 2023 12:00PM Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress
Jun 14, 2023 08:30AM Event-Free Survival Data from Mirum’s LIVMARLI Alagille Syndrome Program Published in Hepatology
Jun 9, 2023 09:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 7, 2023 08:30AM Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress
May 19, 2023 07:00AM Data from Mirum’s LIVMARLI Studies Presented at ESPGHAN Annual Meeting
May 18, 2023 08:30AM Hepatology Communications Publishes Data from Mirum’s LIVMARLI in Primary Sclerosing Cholangitis
May 17, 2023 08:30AM Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting
May 11, 2023 08:30AM Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study
May 10, 2023 09:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2023 04:02PM Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
Apr 27, 2023 04:02PM Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023
Apr 12, 2023 06:59AM Mirum Pharmaceuticals (MIRM) Reports Prelim Q1 Revenue of $31.5M
Apr 12, 2023 06:59AM Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results
Apr 10, 2023 08:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 6, 2023 08:30AM Industry Leader Tim Walbert Joins Mirum Pharmaceuticals’ Board of Directors
Apr 5, 2023 08:30AM Mirum Pharmaceuticals, Inc. (MIRM) Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis
Apr 5, 2023 08:30AM Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis
Mar 14, 2023 08:34AM Mirum Pharmaceuticals (MIRM) Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
Mar 14, 2023 08:30AM Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
Mar 10, 2023 08:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 8, 2023 04:02PM Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update
Mar 1, 2023 09:00AM Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call on March 8, 2023
Feb 14, 2023 08:31AM Mirum Pharmaceuticals, Inc. (MIRM) Submits Supplemental New Drug Application to FDA for LIVMARLI
Feb 14, 2023 08:30AM Mirum Pharmaceuticals Submits Supplemental New Drug Application to FDA for LIVMARLI in Patients with Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis
Feb 10, 2023 11:30PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 9, 2023 09:00AM Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
Jan 10, 2023 09:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 9, 2023 09:03AM Mirum Pharmaceuticals, Inc. (MIRM) Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
Jan 9, 2023 09:00AM Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates
Jan 3, 2023 04:02PM Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
Dec 19, 2022 08:32AM Mirum Pharmaceuticals, Inc. (MIRM) names Lon Cardon to board
Dec 19, 2022 08:30AM Mirum Pharmaceuticals Appoints Lon Cardon to Board of Directors
Dec 13, 2022 03:00AM Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
Dec 9, 2022 07:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 29, 2022 07:31AM Mirum Pharmaceuticals (MIRM) Provides Development Program Updates
Nov 29, 2022 07:30AM Mirum Pharmaceuticals Provides Development Program Updates
Nov 9, 2022 07:30AM Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 7, 2022 01:00PM Mirum Presents New Data from LIVMARLI Phase 3 PFIC Study and ALGS Infant Study in Late-Breaker Presentations at The Liver Meeting of AASLD
Nov 1, 2022 04:05PM Mirum Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
Oct 31, 2022 03:30PM Mirum’s LIVMARLI Data Featured in Two Late-Breaker Presentations at The Liver Meeting of the American Association for the Study of Liver Diseases
Oct 24, 2022 08:31AM Mirum Pharmaceuticals (MIRM) Reports Positive Topline Data from LIVMARLI Phase 3 MARCH Study
Oct 24, 2022 08:30AM Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
Oct 18, 2022 08:30AM Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics
Oct 14, 2022 08:05AM Mirum Pharmaceuticals(MIRM) Announces Positive CHMP Opinion for LIVMARLI Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
Oct 14, 2022 08:05AM Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
Oct 12, 2022 08:31AM Mirum Pharmaceuticals (MIRM) Presents Long-Term LIVMARLI Data and New Alagille Syndrome Caregiver Burden Analysis
Oct 12, 2022 08:30AM Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting
Oct 10, 2022 10:00PM Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories